FAP and metabolic disease: To overcome the limitation of rapid cleavage of hFGF21 by FAP, various approaches have been investigated, such as the attachment of polyethylene glycol to FGF2133–35 and the fusion of FGF21 to an Fc fragment28, as treatments for diabetes and metabolic diseases.